---
figid: PMC2993607__JCI45406.f1
figlink: /pmc/articles/PMC2993607/figure/F1/
number: F1
caption: Different components of the RB pathway are deregulated in human cancers,
  with the overall effect of derepressing E2F transcription factors that promote cell
  cycle progression or programmed cell death. When cell death pathways are inactivated,
  as is the case in most cancers, activation of E2Fs drives proliferation through
  induction of target genes such as cyclin E, CDC6, and CDK1. Loss of the RB1 tumor
  suppressor is prevalent in osteosarcoma and small-cell lung carcinoma (SCLC) in
  addition to its defining loss in human retinoblastoma, but it was initially confounding
  that its loss was not more commonly detected. However, with the discovery that p16/INK4A
  functions as an upstream inhibitor of CDK4 and CDK6 and thus as an activator of
  RB, and that loss of the p16/INK4A locus occurred in many of the cancers where RB1
  loss was not detected, Weinberg and others proposed that functional inactivation
  of RB could be achieved in different tumors through targeting different components
  of the RB pathway (). Thus, loss of p16/INK4A in melanoma, translocation of cyclin
  D1 in mantle cell lymphoma, or, indeed, overexpression of BMI-1 in medulloblastoma
  has been proposed to have similar functional readout to RB loss in terms of E2F
  activity and cellular proliferation. Ampk-α2, α2 subunit of AMPK; Apaf-1, apoptosis
  protease activating factor–1; E2A-Pbx1, the translocation product of fusion of the
  E2A gene to the Pbx1 gene; Emi-1, early mitotic inhibitor 1; FoxO TFs, forkhead
  box O subclass of transcription factors; Tk, thymidine kinase; pol α, DNA polymerase-α.
pmcid: PMC2993607
papertitle: 'The RB tumor suppressor: a gatekeeper to hormone independence in prostate
  cancer?.'
reftext: Kay F. Macleod. J Clin Invest. 2010 Dec 1;120(12):4179-4182.
pmc_ranked_result_index: '83623'
pathway_score: 0.6232009
filename: JCI45406.f1.jpg
figtitle: 'RB tumor suppressor: a gatekeeper to hormone independence in prostate cancer?'
year: '2010'
organisms:
- Homo sapiens
ndex: 5fcbc684-df27-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2993607__JCI45406.f1.html
  '@type': Dataset
  description: Different components of the RB pathway are deregulated in human cancers,
    with the overall effect of derepressing E2F transcription factors that promote
    cell cycle progression or programmed cell death. When cell death pathways are
    inactivated, as is the case in most cancers, activation of E2Fs drives proliferation
    through induction of target genes such as cyclin E, CDC6, and CDK1. Loss of the
    RB1 tumor suppressor is prevalent in osteosarcoma and small-cell lung carcinoma
    (SCLC) in addition to its defining loss in human retinoblastoma, but it was initially
    confounding that its loss was not more commonly detected. However, with the discovery
    that p16/INK4A functions as an upstream inhibitor of CDK4 and CDK6 and thus as
    an activator of RB, and that loss of the p16/INK4A locus occurred in many of the
    cancers where RB1 loss was not detected, Weinberg and others proposed that functional
    inactivation of RB could be achieved in different tumors through targeting different
    components of the RB pathway (). Thus, loss of p16/INK4A in melanoma, translocation
    of cyclin D1 in mantle cell lymphoma, or, indeed, overexpression of BMI-1 in medulloblastoma
    has been proposed to have similar functional readout to RB loss in terms of E2F
    activity and cellular proliferation. Ampk-α2, α2 subunit of AMPK; Apaf-1, apoptosis
    protease activating factor–1; E2A-Pbx1, the translocation product of fusion of
    the E2A gene to the Pbx1 gene; Emi-1, early mitotic inhibitor 1; FoxO TFs, forkhead
    box O subclass of transcription factors; Tk, thymidine kinase; pol α, DNA polymerase-α.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - E2F2
  - CASP3
  - CASP2
  - E2F3
  - CASP1
  - CASP14
  - TGFB3
  - CASP12
  - CASP4
  - CDK4
  - CASP6
  - CDC6
  - CDK6
  - E2F4
  - APAF1
  - PRKAA2
  - GPR162
  - CASP8
  - CASP5
  - CCNA2
  - E2F5
  - BCL2L11
  - CASP9
  - TP73
  - CTNNB1
  - FOXO4
  - BMI1
  - CDK1
  - TGFB2
  - E2F6
  - CASP7
  - E2F7
  - CASP10
  - TGFB1
  - E2F8
  - FBXO5
  - NRAS
  - E2F1
  - CDKN2A
  - FOXO1
  - MYC
  - FOXO3
  - FOXO6
  - HRAS
  - KRAS
  - Cancer
genes:
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F2
  entrez: '1870'
- word: Apaf-1,caspases,p73,
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP3
  entrez: '836'
- word: Apaf-1,caspases,p73,
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP2
  entrez: '835'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F3
  entrez: '1871'
- word: Apaf-1,caspases,p73,
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP1
  entrez: '834'
- word: Apaf-1,caspases,p73,
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP14
  entrez: '23581'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB3
  entrez: '7043'
- word: Apaf-1,caspases,p73,
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP12
  entrez: '100506742'
- word: Apaf-1,caspases,p73,
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP4
  entrez: '837'
- word: Cdk4/6
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: Apaf-1,caspases,p73,
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP6
  entrez: '839'
- word: Cdc6,
  symbol: CDC6
  source: hgnc_symbol
  hgnc_symbol: CDC6
  entrez: '990'
- word: Cdk4/6
  symbol: CDK6
  source: hgnc_symbol
  hgnc_symbol: CDK6
  entrez: '1021'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F4
  entrez: '1874'
- word: Apaf-1,caspases,p73,
  symbol: APAF-1
  source: hgnc_alias_symbol
  hgnc_symbol: APAF1
  entrez: '317'
- word: Ampk-a2
  symbol: AMPKa2
  source: hgnc_alias_symbol
  hgnc_symbol: PRKAA2
  entrez: '5563'
- word: A2
  symbol: A-2
  source: hgnc_alias_symbol
  hgnc_symbol: GPR162
  entrez: '27239'
- word: Apaf-1,caspases,p73,
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP8
  entrez: '841'
- word: Apaf-1,caspases,p73,
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP5
  entrez: '838'
- word: Emi-1,Cdk1,cyclinA2
  symbol: Cyclin-A2
  source: bioentities_symbol
  hgnc_symbol: CCNA2
  entrez: '890'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F5
  entrez: '1875'
- word: Bim,
  symbol: BIM
  source: hgnc_alias_symbol
  hgnc_symbol: BCL2L11
  entrez: '10018'
- word: Apaf-1,caspases,p73,
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP9
  entrez: '842'
- word: Apaf-1,caspases,p73,
  symbol: P73
  source: hgnc_alias_symbol
  hgnc_symbol: TP73
  entrez: '7161'
- word: B-catenin
  symbol: beta-catenin
  source: hgnc_alias_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: FoxO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO4
  entrez: '4303'
- word: Bmi-1
  symbol: BMI1
  source: hgnc_symbol
  hgnc_symbol: BMI1
  entrez: '648'
- word: Emi-1,Cdk1,cyclinA2
  symbol: CDK1
  source: hgnc_symbol
  hgnc_symbol: CDK1
  entrez: '983'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB2
  entrez: '7042'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F6
  entrez: '1876'
- word: Apaf-1,caspases,p73,
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP7
  entrez: '840'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F7
  entrez: '144455'
- word: Apaf-1,caspases,p73,
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP10
  entrez: '843'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB1
  entrez: '7040'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F8
  entrez: '79733'
- word: Emi-1,
  symbol: EMI1
  source: hgnc_alias_symbol
  hgnc_symbol: FBXO5
  entrez: '26271'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F1
  entrez: '1869'
- word: p16
  symbol: p16
  source: hgnc_alias_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: FoxO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO1
  entrez: '2308'
- word: Myc
  symbol: MYC
  source: hgnc_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: FoxO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO3
  entrez: '2309'
- word: FoxO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO6
  entrez: '100132074'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC2993607__F1
redirect_from: /figures/PMC2993607__F1
figtype: Figure
---
